FIELD: medicine.
SUBSTANCE: invention refers to medicine, biotechnology and genetic engineering. What is described is a complex of StCas9 protein and a new RNA-conductor for suppression of hepatitis B virus expression in a host cell and for elimination of hepatitis B virus DNA from a host cell, such as a mammalian cell. Also described is use of StCas9 protein combined with RNA-conductor to suppress hepatitis B virus expression in a host cell and for DNA degradation of hepatitis B virus and its elimination from a host cell, including annular covalently closed DNA, from said host cell. Said RNA-conductor is formed by the first nucleotide sequence SEQ ID NO: 1 (AGAAAGGCCTTGTAAGTTGG) and a second nucleotide sequence, which is an RNA-pin flanking said first sequence from 3'-end and characterized by a sequence SEQ ID NO: 2 (AACGCGGUCGCCAAAGAGAUGUUUUUGUACUCUGGUACCAGAAGCUACAAAGAUAAGGCUUCAUGCCGAAAUCAACA CCCUGUCAUUUUAUGGCAGGGUGUUUU) and structure, presented in fig. 1. Said first sequence is able to bind to the target highly conserved portion of hepatitis B virus DNA. Said second sequence is capable of attracting the protein-endonuclease Cas9 Streptococcus thermophilus (StCas9) to said target highly conserved portion of viral DNA with ensuring the degradation of said hepatitis B virus DNA by said StCas9 endonuclease protein without the formation of off-target gaps in the human genome.
EFFECT: invention provides a new agent for influencing DNA of hepatitis B virus – RNA-conductor St10 in complex with StCas9 protein, allowing to affect DNA of hepatitis B virus, wherein target of said RNA-conductor is conservative in many clinically significant genotypes of hepatitis B virus (genotypes A, B, C, D, E and H), thereby providing degradation of said DNA and its elimination from host cell.
20 cl, 9 dwg, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
RNA-CONDUCTORS TO SUPPRESS THE REPLICATION OF HEPATITIS B VIRUS AND FOR THE ELIMINATION OF HEPATITIS B VIRUS FROM HOST CELL | 2017 |
|
RU2652899C1 |
SYSTEM FOR ACTIVATING HUMAN APOBEC/AID CYTIDINE DEAMINASES AND/OR HUMAN URACIL-DNA-GLYCOSYLASE UNG AND ITS USE FOR ELIMINATING CCC DNA OF HEPATITIS B VIRUS FROM HUMAN CELLS, PARTICULARLY HEPATOCYTES | 2018 |
|
RU2703532C1 |
CRISPR-CAS12 SYSTEM FOR DETECTING HEPATITIS C VIRUS RNA GENOTYPES 1B AND 3A AT ULTRA-LOW CONCENTRATIONS | 2022 |
|
RU2800421C1 |
METHOD OF DETECTION OF RNA OF HEPATITIS C VIRUS GENOTYPES 1B AND 3A IN ULTRA-LOW CONCENTRATIONS AND SPECIFIC OLIGONUCLEOTIDES FOR USE IN THE METHOD | 2022 |
|
RU2800420C1 |
METHOD OF PRODUCING A PREPARATION OF A RIBONUCLEOPROTEIN COMPLEX CRISPR-CAS AND A PREPARATION FOR DETECTING HEPATITIS C VIRUS RNA OF GENOTYPES 1B AND 3A IN ULTRA-LOW CONCENTRATIONS | 2022 |
|
RU2799430C1 |
RNA-GUIDED HUMAN GENOME ENGINEERING | 2013 |
|
RU2766685C2 |
RNA-GUIDED ENGINEERING OF HUMAN GENOME | 2013 |
|
RU2699523C2 |
MOLECULE OF RNA-CONDUCTOR SGRNA FOR INTRODUCING MUTATIONS INTO CONSERVED REGION OF COMMON WHEAT PPD-D1 GENE PROMOTER REGION USING CRISPR/CAS9 GENOME EDITING SYSTEM | 2024 |
|
RU2822358C1 |
DESIGNING SYSTEMS, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR MANIPULATING SEQUENCES | 2013 |
|
RU2701850C2 |
RNA-CONDUCTOR MOLECULE FOR GENOMIC EDITING OF PROMOTER REGION OF VRN-A1 GENE OF MONOCOTYLEDONOUS CEREALS USING CRISPR/CAS9 SYSTEM | 2020 |
|
RU2762831C1 |
Authors
Dates
2019-07-12—Published
2018-12-14—Filed